Target NLRP3 therapy (Secarna)

N/A

Report date: 2024/09/13 13:57:21
NME

Base Information

Drug NameTarget NLRP3 therapy (Secarna)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 modulators
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsInflammationFibrosisMetabolic Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSecarna Pharmaceuticals GmbH & Co KG
China Registration ClassN/A

Develop Information

Active CompaniesSecarna Pharmaceuticals GmbH & Co KG
Inactive CompaniesN/A
Active IndicationsInflammationFibrosisMetabolic Diseases +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A